Edwards Lifesciences PE Ratio 2012-2026 | EW
Current and historical p/e ratio for Edwards Lifesciences (EW) from 2012 to 2026. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Edwards Lifesciences PE ratio as of June 11, 2026 is 30.42.
| Edwards Lifesciences PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2026-06-11 | 85.76 | 45.62 | |
| 2026-03-31 | 80.08 | $1.88 | 42.60 |
| 2025-12-31 | 85.25 | $1.83 | 46.58 |
| 2025-09-30 | 77.77 | $2.32 | 33.52 |
| 2025-06-30 | 78.21 | $6.95 | 11.25 |
| 2025-03-31 | 72.48 | $7.00 | 10.35 |
| 2024-12-31 | 74.03 | $6.97 | 10.62 |
| 2024-09-30 | 65.99 | $6.93 | 9.52 |
| 2024-06-30 | 92.37 | $2.43 | 38.01 |
| 2024-03-31 | 95.56 | $2.32 | 41.19 |
| 2023-12-31 | 76.25 | $2.30 | 33.15 |
| 2023-09-30 | 69.28 | $2.34 | 29.61 |
| 2023-06-30 | 94.33 | $2.26 | 41.74 |
| 2023-03-31 | 82.73 | $2.41 | 34.33 |
| 2022-12-31 | 74.61 | $2.44 | 30.58 |
| 2022-09-30 | 82.63 | $2.31 | 35.77 |
| 2022-06-30 | 95.09 | $2.30 | 41.34 |
| 2022-03-31 | 117.72 | $2.43 | 48.44 |
| 2021-12-31 | 129.55 | $2.38 | 54.43 |
| 2021-09-30 | 113.21 | $2.35 | 48.17 |
| 2021-06-30 | 103.57 | $2.33 | 44.45 |
| 2021-03-31 | 83.64 | $1.35 | 61.96 |
| 2020-12-31 | 91.23 | $1.30 | 70.18 |
| 2020-09-30 | 79.82 | $1.25 | 64.03 |
| 2020-06-30 | 69.11 | $1.16 | 59.75 |
| 2020-03-31 | 62.87 | $1.74 | 36.20 |
| 2019-12-31 | 77.76 | $1.64 | 47.42 |
| 2019-09-30 | 73.30 | $1.22 | 60.08 |
| 2019-06-30 | 61.58 | $1.14 | 53.86 |
| 2019-03-31 | 63.78 | $1.20 | 53.00 |
| 2018-12-31 | 51.06 | $1.13 | 45.18 |
| 2018-09-30 | 58.03 | $1.11 | 52.28 |
| 2018-06-30 | 48.52 | $1.02 | 47.57 |
| 2018-03-31 | 46.51 | $0.87 | 53.66 |
| 2017-12-31 | 37.57 | $0.90 | 41.74 |
| 2017-09-30 | 36.44 | $1.14 | 31.87 |
| 2017-06-30 | 39.41 | $1.10 | 35.94 |
| 2017-03-31 | 31.36 | $1.00 | 31.25 |
| 2016-12-31 | 31.23 | $0.87 | 35.90 |
| 2016-09-30 | 40.19 | $0.84 | 47.65 |
| 2016-06-30 | 33.24 | $0.81 | 41.21 |
| 2016-03-31 | 29.40 | $0.78 | 37.54 |
| 2015-12-31 | 26.33 | $0.75 | 35.10 |
| 2015-09-30 | 23.70 | $0.70 | 34.01 |
| 2015-06-30 | 23.74 | $0.66 | 35.87 |
| 2015-03-31 | 23.74 | $1.34 | 17.72 |
| 2014-12-31 | 21.23 | $1.25 | 17.03 |
| 2014-09-30 | 17.03 | $1.20 | 14.17 |
| 2014-06-30 | 14.31 | $1.17 | 12.23 |
| 2014-03-31 | 12.36 | $0.46 | 27.07 |
| 2013-12-31 | 10.96 | $0.57 | 19.23 |
| 2013-09-30 | 11.61 | $0.58 | 19.95 |
| 2013-06-30 | 11.20 | $0.57 | 19.82 |
| 2013-03-31 | 13.69 | $0.53 | 26.08 |
| 2012-12-31 | 15.03 | $0.41 | 36.65 |
| 2012-09-30 | 17.90 | $0.37 | 47.92 |
| 2012-06-30 | 17.22 | $0.35 | 49.42 |
| 2012-03-31 | 12.12 | $0.33 | 36.36 |
| 2011-12-31 | 11.78 | $0.33 | 35.71 |
| 2011-09-30 | 11.88 | $0.33 | 35.82 |
| 2011-06-30 | 14.53 | $0.33 | 44.48 |
| 2011-03-31 | 14.50 | $0.33 | 44.38 |
| 2010-12-31 | 13.47 | $0.31 | 44.16 |
| 2010-09-30 | 11.18 | $0.28 | 40.03 |
| 2010-06-30 | 9.34 | $0.32 | 29.41 |
| 2010-03-31 | 8.24 | $0.31 | 26.95 |
| 2009-12-31 | 7.24 | $0.32 | 22.28 |
| 2009-09-30 | 5.83 | $0.31 | 18.55 |
| 2009-06-30 | 5.67 | $0.26 | 22.16 |
| 2009-03-31 | 5.05 | $0.24 | 20.77 |
| 2008-12-31 | 4.58 | $0.18 | 24.98 |
| 2008-09-30 | 4.81 | $0.15 | 31.75 |
| 2008-06-30 | 5.17 | $0.14 | 35.68 |
| 2008-03-31 | 3.71 | $0.14 | 27.18 |
| 2007-12-31 | 3.83 | $0.16 | 24.60 |
| 2007-09-30 | 4.11 | $0.16 | 25.55 |
| 2007-06-30 | 4.11 | $0.16 | 25.97 |
| 2007-03-31 | 4.23 | $0.16 | 26.56 |
| 2006-12-31 | 3.92 | $0.17 | 22.41 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Instruments Manufacturing | $44.895B | $6.068B |
| Edwards Lifesciences Corporation deals in products and technologies aimed at treating advanced cardiovascular diseases, especially structural heart disease in critically ill patients. The company is the world's leading manufacturer of tissue heart valves and repair products used to replace or repair a patient's diseased or defective heart valve. Edwards is also a leading player in hemodynamic monitoring systems used to measure a patient's cardiovascular function in the hospital setting. The company's products and technologies are categorized into four main areas: Transcatheter Aortic Valve Replacement (TAVR), Transcatheter Mitral and Tricuspid Therapies (TMTT), Surgical Structural Heart, and Critical Care. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Thermo Fisher Scientific (TMO) | United States | $184.365B | 21.69 |
| Intuitive Surgical (ISRG) | United States | $160.029B | 61.73 |
| IDEXX Laboratories (IDXX) | United States | $44.716B | 43.08 |
| Alcon (ALC) | Switzerland | $38.585B | 25.49 |
| Waters (WAT) | United States | $31.413B | 24.37 |
| IQVIA Holdings (IQV) | United States | $28.398B | 15.40 |
| Mettler-Toledo (MTD) | United States | $26.829B | 30.97 |
| DexCom (DXCM) | United States | $24.639B | 30.63 |
| STERIS (STE) | Ireland | $21.830B | 22.08 |
| Hologic (HOLX) | United States | $16.752B | 17.53 |
| Coloplast (CLPBY) | Denmark | $15.055B | 23.03 |
| SONOVA HOLDING (SONVY) | Switzerland | $13.774B | 0.00 |
| Fresenius Medical Care AG KGaA (FMS) | Germany | $13.199B | 9.72 |
| Penumbra (PEN) | United States | $12.941B | 85.88 |
| Globus Medical (GMED) | United States | $12.230B | 22.60 |
| Masimo (MASI) | United States | $9.578B | 30.69 |
| Glaukos (GKOS) | United States | $6.760B | 0.00 |
| SARTORIUS (SSSGY) | Germany | $6.754B | 39.22 |
| Sysmex ADR (SSMXY) | Japan | $5.470B | 18.10 |
| Teleflex (TFX) | United States | $5.233B | 9.67 |
| TransMedics (TMDX) | United States | $3.910B | 40.00 |
| LivaNova (LIVN) | United Kingdom | $3.433B | 18.41 |
| Integer Holdings (ITGR) | United States | $2.900B | 13.28 |
| Veracyte (VCYT) | United States | $2.470B | 24.48 |
| Elekta AB (EKTAY) | Sweden | $2.226B | 20.13 |
| Artivion (AORT) | United States | $1.825B | 59.73 |
| AxoGen (AXGN) | United States | $1.659B | 0.00 |
| Alphatec Holdings (ATEC) | United States | $1.650B | 0.00 |
| Nihon Kohden (NHNKY) | Japan | $1.642B | 18.12 |
| UFP Technologies (UFPT) | United States | $1.552B | 20.54 |
| Tandem Diabetes Care (TNDM) | United States | $1.314B | 0.00 |
| PROCEPT BioRobotics (PRCT) | United States | $1.308B | 0.00 |
| Pulse Biosciences (PLSE) | United States | $1.269B | 0.00 |
| IRadimed (IRMD) | United States | $1.194B | 53.37 |
| OPKO Health (OPK) | United States | $0.881B | 0.00 |
| Integra LifeSciences Holdings (IART) | United States | $0.772B | 4.44 |
| AVANOS MEDICAL, INC (AVNS) | United States | $0.659B | 15.09 |
| Alpha Tau Medical (DRTS) | Israel | $0.618B | 0.00 |
| SiBone (SIBN) | United States | $0.567B | 0.00 |
| Anteris Technologies Global (AVR) | Australia | $0.552B | 0.00 |
| Tactile Systems Technology (TCMD) | United States | $0.533B | 28.23 |
| Mesa Laboratories (MLAB) | United States | $0.530B | 13.79 |
| ORTHOFIX MEDICAL INC (OFIX) | United States | $0.497B | 0.00 |
| NeuroPace (NPCE) | United States | $0.480B | 0.00 |
| AngioDynamics (ANGO) | United States | $0.405B | 0.00 |
| Pacific Biosciences Of California (PACB) | United States | $0.405B | 0.00 |
| OrthoPediatrics (KIDS) | United States | $0.404B | 0.00 |
| Beta Bionics (BBNX) | United States | $0.393B | 0.00 |
| Delcath Systems (DCTH) | United States | $0.346B | 143.43 |
| Semler Scientific (SMLR) | United States | $0.311B | 2.32 |
| Spectral Diagnostics (EDTXF) | Canada | $0.296B | 0.00 |
| RxSight (RXST) | United States | $0.282B | 0.00 |
| 908 Devices (MASS) | United States | $0.267B | 0.00 |
| ClearPoint Neuro (CLPT) | United States | $0.257B | 0.00 |
| Lucid Diagnostics (LUCD) | United States | $0.203B | 0.00 |
| CVRx (CVRX) | United States | $0.188B | 0.00 |
| Sight Sciences (SGHT) | United States | $0.186B | 0.00 |
| Microbot Medical (MBOT) | United States | $0.174B | 0.00 |
| Inogen (INGN) | United States | $0.172B | 0.00 |
| Nano-X Imaging (NNOX) | Israel | $0.148B | 0.00 |
| EDAP TMS S.A (EDAP) | France | $0.124B | 0.00 |
| Hyperfine (HYPR) | United States | $0.119B | 0.00 |
| Treace Medical Concepts (TMCI) | United States | $0.117B | 0.00 |
| Zomedica (ZOMDF) | United States | $0.111B | 0.00 |
| Solana (HSDT) | United States | $0.104B | 0.00 |
| Rapid Micro Biosystems (RPID) | United States | $0.096B | 0.00 |
| Neuronetics (STIM) | United States | $0.094B | 0.00 |
| QT Imaging Holdings (QTI) | United States | $0.083B | 0.00 |
| QT Imaging Holdings (QTIH) | United States | $0.078B | 0.00 |
| Sensus Healthcare (SRTS) | United States | $0.074B | 0.00 |
| LENSAR (LNSR) | United States | $0.069B | 0.00 |
| Positron (POSC) | United States | $0.062B | 0.00 |
| InspireMD (NSPR) | United States | $0.060B | 0.00 |
| Spectral AI (MDAI) | United States | $0.055B | 0.00 |
| DarioHealth (DRIO) | United States | $0.053B | 0.00 |
| Envoy Medical (COCH) | United States | $0.047B | 0.00 |
| Baird Medical Investment Holdings (BDMD) | $0.047B | 0.00 | |
| Accuray (ARAY) | United States | $0.046B | 0.00 |
| Atossa Genetics (ATOS) | United States | $0.043B | 0.00 |
| Precision Optics (POCI) | United States | $0.032B | 0.00 |
| Ekso Bionics Holdings (EKSO) | United States | $0.032B | 0.00 |
| Adagio Medical Holdings (ADGM) | United States | $0.028B | 0.00 |
| Check-Cap (MBAI) | Israel | $0.012B | 0.00 |
| SINTX TECHNOLOGIES, INC (SINT) | United States | $0.011B | 0.00 |
| PAVmed (PAVM) | United States | $0.009B | 0.00 |
| Tenon Medical (TNON) | United States | $0.009B | 0.00 |
| EnVVeno Medical (NVNO) | United States | $0.007B | 0.00 |
| ENDRA Life Sciences (NDRA) | United States | $0.006B | 0.00 |
| NexGel (NXGL) | United States | $0.005B | 0.00 |
| Nanovibronix (NAOV) | United States | $0.004B | 0.00 |
| Nuwellis (NUWE) | United States | $0.003B | 0.00 |
| Autonomix Medical (AMIX) | United States | $0.003B | 0.00 |
| ENvue Medical (FEED) | United States | $0.002B | 0.00 |
| Bluejay Diagnostics (BJDX) | United States | $0.002B | 0.00 |
| WORK Medical Technology Group (WOK) | China | $0.000B | 0.00 |
| Spinal Elements Holdings (SPEL) | United States | $0.000B | 0.00 |
| Inspira Technologies OXY B.H.N (IINN) | Israel | $0.000B | 0.00 |
| Longview Acquisition II (LGV) | United States | $0.000B | 0.00 |